BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $4 to $3.
BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $4 to $3.